A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study - Wikidata - wikimedia - TriplyDB

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

http://www.wikidata.org/entity/Q28293805

about

A phase 2 study of vorinostat in acute myeloid leukemia An update of current treatments for adult acute myeloid leukemia Progress in acute myeloid leukemia 'Acute myeloid leukemia: a comprehensive review and 2016 update'Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.Is there a standard induction regimen for patients with AML?Challenges in treating older patients with acute myeloid leukemia.Allogeneic hematopoietic cell transplantation: the state of the art High-dose cytarabine in acute myeloid leukemia treatment: a systematic review and meta-analysis.Anthracycline dose intensification in acute myeloid leukemia.Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.miR-181a modulates acute myeloid leukemia susceptibility to natural killer cells.Retrospective analysis of 119 cases of pediatric acute promyelocytic leukemia: Comparisons of four treatment regimes.Allogeneic stem cell transplantation in acute myeloid leukemia Anthracycline dose intensification in young adults with acute myeloid leukemia.A comparative study of idarubicin 12 mg/m(2) and 8 mg/m(2) combined with cytarabine as the first induction regimen for adult acute myeloid leukemia patients.Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.Genetic factors influencing cytarabine therapy.Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus The evolving landscape in the therapy of acute myeloid leukemia.A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation.Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis.Update on optimal management of acute myeloid leukemia Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia.

P2860

Q24643266-51BA5217-0CD9-43AE-8D3B-18556496CD05 Q26776396-05D1348B-22A3-49B2-837B-CD59A45F35F4 Q27024006-9194962E-BB1F-4314-B3A4-8BE823FFDF51 Q28072539-8B2507FD-625E-425D-9A9C-E2F53DCE007E Q30444746-F2BDBAC5-A771-4D7E-BE53-6341B1D65681 Q33903024-478F6FD8-DBB6-4219-B5FB-25B93AEBA4B8 Q33952411-A0138B2C-42B7-45D5-8980-DDC9C6D98AD8 Q33985549-77915FE8-7B8B-431E-808C-7463CD77A89D Q34145155-AA257472-757E-4E61-BF78-4140CFAF5510 Q34317679-19EBCA1A-0FFD-4C01-832C-205C53D12FEF Q34612121-E48B9D88-3D8B-4D9F-A294-4475CB39336D Q35209900-5A478D53-5E35-435A-B024-F3B6913F485F Q35584427-08A765F2-07F5-4BD3-8A11-F4A4BDC44E35 Q35750919-998AFA5D-9D1F-4862-A7E0-2055DC5051E7 Q35859437-AD2BB6F5-6FF0-480F-885F-77BF34AA8E81 Q36053792-DF822E31-E487-4E6B-A1E5-9076E23A8708 Q36152664-B10BAF13-ACD5-439D-98B1-5669054DABD9 Q36219674-62C0AC2E-3DA9-4BA8-97AB-928BE4CC3594 Q36256357-4A9C4FE0-7122-4F2E-A9CC-B82511D2FE70 Q36285651-7090EED1-35D0-4EED-8AD2-4EEFAA233D0B Q36562937-08624E28-833D-4BC2-B28C-FAE51C95173A Q36612663-57226CDA-FBC2-4A15-86BA-BEF9F3416007 Q36653102-16A53822-B812-4717-9028-82B1C5947520 Q36727867-1CC70173-0F9C-4D40-ADBE-CF1CA2A5F33C Q37006786-C40DD11F-8FCB-4C68-BC93-0F67CDB6D6B2 Q37071108-3A4B9BBF-0E6C-4DCB-85A8-3234E8AECEA2 Q37166414-51C014D8-2434-4D91-AB14-E74D8AEE9316 Q37271941-D2ED5964-CD9B-4F12-8C8E-2A4CDB61DFEF Q37323006-FB491087-429B-437E-A595-CA3052C270C5 Q37324869-5BF82552-6BF8-4DC0-8669-27D1CE0225AC Q37364509-1F1AF3EB-894D-40B4-913E-567C7FC87610 Q37618228-9B02786F-F31A-4139-ABDB-1115EF75E1E4 Q37624076-B437807D-8794-4EC4-8ADA-6DD03C56A699 Q37625632-37F774AB-0829-4D2F-84C1-A353212C146C Q38106983-8DE01D66-B123-4B39-ACE6-7D1F53E34080 Q38132064-FCB0B850-C9E9-4A49-9FF7-3C064E3412C0 Q40815983-722D4296-5266-476C-9A05-61B5C4D3A5F1 Q41530049-66F9AFE9-0C74-45B2-A3D3-8D6A90EE7F48 Q41894404-FAC66824-9865-4FA6-A7DB-DB638E70220B Q42377773-CC57DE2D-715F-4C4B-81C1-BA04833CC1F5

P2860

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

http://www.wikidata.org/entity/Q28293805

description

1996 nî lūn-bûn

@nan

1996 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年学术文章

@wuu

1996年学术文章

@zh-cn

1996年学术文章

@zh-hans

1996年学术文章

@zh-my

1996年学术文章

@zh-sg

1996年學術文章

@yue

name

A randomized investigation of ...... Southwest Oncology Group study

@ast

A randomized investigation of ...... Southwest Oncology Group study

@en

A randomized investigation of ...... Southwest Oncology Group study

@nl

type

label

A randomized investigation of ...... Southwest Oncology Group study

@ast

A randomized investigation of ...... Southwest Oncology Group study

@en

A randomized investigation of ...... Southwest Oncology Group study

@nl

prefLabel

A randomized investigation of ...... Southwest Oncology Group study

@ast

A randomized investigation of ...... Southwest Oncology Group study

@en

A randomized investigation of ...... Southwest Oncology Group study

@nl

P1433

Q28293805-EC5E4EB1-E206-42A3-B366-454BC1E35B18

P1476

Q28293805-E9B2423C-A53F-41A6-B266-E05430BC13EA

P2093

Q28293805-00BDF8D6-F7DB-4A68-B9FA-4FFEB375FEF1

Q28293805-06CB7477-10BC-4B06-BD1E-94ADB004302B

Q28293805-125DA423-2FFB-4A16-8EDC-CF5FC7889638

Q28293805-1CCEB686-CC5A-4DAB-A4E6-BA71806BF5DA

Q28293805-3149279E-8E65-454E-9A9A-693112EA9586

Q28293805-5A0888B7-FD49-4374-8107-7B0A092B91C6

Q28293805-B4E6E590-996F-4AF9-AAA4-75ECADF847CE

Q28293805-C3F4C122-A14A-4014-AF72-4A81168C62E7

Q28293805-ECE01C42-FCFF-496A-AC17-CA8E6C4C98BB

Q28293805-F64C3E39-44D6-4ACE-9CED-C9F933357AEB

P304

Q28293805-D7FDA657-C1BC-4E71-8202-76416BB911DD

P31

Q28293805-CB5DC885-D020-4837-AF1D-F2A29DC0C189

P3181

Q28293805-BFC49CAB-DB95-4692-8468-12F4D9252567

P407

Q28293805-A872C68A-1156-4798-B052-265E4AB98D2D

P433

Q28293805-82E60AD6-05CE-4E18-8ADF-ACF9C042AC8D

P478

Q28293805-82175517-A3D2-4AF1-A018-25CA4B5CEB17

P50

Q28293805-0BEFB681-E80B-44AD-BF54-9A0CE2BB11E1

P577

Q28293805-C35523FD-711F-42FE-9147-836B355A3071

P698

Q28293805-DABAFA12-965D-49C3-8F4A-821A3F4D50D4

P921

Q28293805-993420D0-1E1B-46EC-A446-8AC627DA3C45

Q28293805-E8E40992-EB8F-41D4-899B-C41FBF5583B9

P3181

P1433

P1476

A randomized investigation of ...... Southwest Oncology Group study

@en

P2093

Balcerzak SP

http://www.w3.org/2001/XMLSchema#string

Bickers JN

http://www.w3.org/2001/XMLSchema#string

Grever M

http://www.w3.org/2001/XMLSchema#string

Head DR

http://www.w3.org/2001/XMLSchema#string

Hynes HE

http://www.w3.org/2001/XMLSchema#string

Kingsbury LL

http://www.w3.org/2001/XMLSchema#string

Kopecky KJ

http://www.w3.org/2001/XMLSchema#string

Simon SR

http://www.w3.org/2001/XMLSchema#string

Weick JK

http://www.w3.org/2001/XMLSchema#string

Welborn JL

http://www.w3.org/2001/XMLSchema#string

P304

2841-2851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4707056

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

88

http://www.w3.org/2001/XMLSchema#string

P50

Frederick R. Appelbaum

P577

1996-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8874180

http://www.w3.org/2001/XMLSchema#string

P921